PHS HIRING FREEZE THREATENS DEVICE USER FEE NEGOTIATIONS
This article was originally published in The Gray Sheet
Executive Summary
PHS HIRING FREEZE THREATENS DEVICE USER FEE NEGOTIATIONS between industry and FDA, the Health Industry Manufacturers Association says in a Dec. 22 letter to HHS Assistant Secretary for Health Philip Lee. The Public Health Service hiring freeze, which went into effect Dec. 8 ("The Gray Sheet" Dec. 20, I&W-1), "jeopardizes current negotiations between industry and the agency with respect to user fees designed to enhance the performance of the Center for Devices and Radiological Health," HIMA asserts. The association appears to be concerned that the freeze could hamper FDA's, ability to meet performance goals that will likely be part of device user fee legislation.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.